## Table 2: Level 1 Checklist for Screening Titles and Abstracts

| Reviewer: _____ Date: _____ | | | |
|---|---|---|---|
| **Ref ID:**<br>**Author:**<br>**Publication Year:** | | | |
| **Did the study include:** | **Yes (Include)** | **Unclear (Include)[a]** | **No (Exclude)** |
| **A. The population of interest:** | | | |
| • Adults (mean age of ≥ 18 years) with r/r-DLBCL | ☐ | ☐ | ☐ |
| • Mixed, with ≥ 80% being adults with r/r-DLBCL | ☐ | ☐ | ☐ |
| • Pediatric or young adult (≤ 25 years) with r/r-ALL | ☐ | ☐ | ☐ |
| • Mixed, with ≥ 80% being pediatric or young adult (⩽25 years) with r/r-ALL | ☐ | ☐ | ☐ |
| **B. The intervention of interest:** | | | |
| • Tisagenlecleucel alone | ☐ | ☐ | ☐ |
| • Tisagenlecleucel together with drug interventions | ☐ | ☐ | ☐ |
| • Tisagenlecleucel together with HSCT | ☐ | ☐ | ☐ |
| **C. The comparator(s) of interest:** | | | |
| • Other Car T-cell therapies | ☐ | ☐ | ☐ |
| • Conventional salvage therapy<br>• Allogenic HSCT | ☐ | ☐ | ☐ |
| • No Comparator | ☐ | ☐ | ☐ |
| **D. The outcome(s) of interest:** | | | |
| • Objective efficacy outcomes (e.g., CR, PR, OS, PFS, etc.) | ☐ | ☐ | ☐ |
| • Quality of life | ☐ | ☐ | ☐ |
| • Safety outcomes such as AEs (e.g., CRS, prolonged cytopenias, infections and infestations, febrile neutropenia, neurological effects including hallucination and dysphasia, etc.) SAEs (i.e., Grade ≥ 3 AEs), and WDAEs | ☐ | ☐ | ☐ |
| **E. The study design(s) of interest:** | | | |
| • RCTs | ☐ | ☐ | ☐ |
| • Non-randomized controlled trials<br>• Single-arm studies | ☐ | ☐ | ☐ |
| • Cohort studies | ☐ | ☐ | ☐ |
| • Case-control studies | ☐ | ☐ | ☐ |
| **F. Select for full-text review [b]** | **Yes ☐** | | **No ☐** |

AE= adverse event; CAR = chimeric antigen receptor; CR = complete remission; CRS = cytokine release syndrome; HSCT = hematopoietic stem cell transplant; OS = overall survival; PFS = progression-free survival; PR = partial remission; RCT = randomized controlled trial; WDAE = withdrawal due to adverse event.

[a] "Unclear" means that it cannot be ascertained from the title or abstract if the report is potentially relevant to the review.

[b] The full-text article of any title or abstract will be retrieved for further review if the response to all screening items above-noted are either "Yes" or "Unclear" by at least one of two independent reviewers.